Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498430 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL8536163 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL10601287 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL5180047 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL5178380 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL5179103 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL9417254 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL5180698 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL2497008 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 | |
| SCHEMBL9351933 | 1.00 | USP2 (0.53) | USP2LPAR5HTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101407-B1 | KIT AND METHOD FOR ELECTRON MICROSCOPE OBSERVATION | JAPAN SCIENCE & TECH AGENCY (JP) | 2023-03-08 | — | — | EP | disclosed |
| EP-1031348-B1 | Interleukin-4 production inhibitors | KAO CORP (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-6974596-B2 | Interleukin-4 production inhibitors | KAO CORPORATION (JP) | 2005-12-13 | — | — | US | disclosed |
| US-6960359-B2 | Interleukin-4 production inhibitors | KAO CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| EP-0965327-B1 | WRINKLING MODIFIERS | KAO CORP (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20030129265-A1 | Interleukin-4 production inhibitors | KAO CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030129266-A1 | Comprising cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol; antiallergic agents and atopic dermatitis preventives | KAO CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6495171-B2 | BATH MEDICINE; ANTIALLERGENS, SKIN DISORDERS | KAO CORPORATION (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-0808625-B1 | External skin-care composition | KAO CORP (JP) | 2002-08-07 | — | — | EP | disclosed |
| US-20010031285-A1 | Interleukin-4 production inhibitors | KAO CORPORATION (JP) | 2001-10-18 | — | — | US | disclosed |
| EP-1031348-A2 | Interleukin-4 production inhibitors | Kao Corporation (JP) | 2000-08-30 | — | — | EP | disclosed |
| EP-0965327-A1 | WRINKLING MODIFIERS | Kao Corporation (JP) | 1999-12-22 | — | — | EP | disclosed |
| EP-0808625-A1 | External skin-care composition | Kao Corporation (JP) | 1997-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129265-A1 | Interleukin-4 production inhibitors | IL4, IL33, IL36G | USP2 3647/4885LPAR5 1747/4885HTT 4551/4885 |
| US-20010031285-A1 | Interleukin-4 production inhibitors | IL4, IL33, IL36G | USP2 3647/4885LPAR5 1747/4885HTT 4551/4885 |
| US-20030129266-A1 | Comprising cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol; antiallergic agents and atopic dermatitis preventives | IL4, IL33, IL36G | USP2 3608/4885LPAR5 1311/4885HTT 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.